A Phase 1 interventional study of DWP16001 and DWC202204+DWC202205 in Healthy, sponsored by Daewoong Pharmaceutical Co. LTD.. Status unknown. Open to male participants aged 19 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-08-15.
Sponsored by Daewoong Pharmaceutical Co. LTD. · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to evaluate drug-drug interaction by comparing the pharmacokinetics (PK)/pharmacodynamics (PD), safety, and tolerability of single/multiple doses of DWP16001 , DWC202204 and DWC202205 alone or in combination in healthy male adults.
* Open label, multiple dose, 2 part, two period, single sequence design. This study is conducted on open label because it evaluates PK/PD parameters that are not affected by the blind. Volunteers who are suitable for the inclusion criteria are granted the final target number before the first dosage, receiving a fixed IP, and conducting a planned clinical trial schedule.
After having a rest period (7 days) in which the drug received is sufficiently metabolized and lost, the IP of the next period is administered.
Daewoong Pharmaceutical Co. LTD. is the lead sponsor of 200 studies on the registry; 33 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: DWP16001
Drug: DWC202204+DWC202205
Drug: DWP16001+DWC202204+DWC202205
Tablets, Oral, multiple doses of DWP16001
Tablets, Oral, multiple doses of DWC202204 and DWC202205 in combination
Drug page: Enavogliflozin
Tablets, Oral, DWP16001 , multiple doses of DWC202204 and DWC202205 in combination
Cmax,ss of DWP16001
Peak Plasma Concetration at steady-state
Time frame: [Time Frame: 0-72 hours]
AUCtau,ss of DWP16001
Area under the plasma concentration versus time curve at Tau, steady-state
Time frame: [Time Frame: 0-72 hours]
Cmax,ss of DWC202204 and DWC202205
Peak Plasma Concetration at steady-state
Time frame: [Time Frame: 0-24 hours]
AUCtau,ss of DWC202204 and DWC202205
Area under the plasma concentration versus time curve at Tau, steady-state
Time frame: [Time Frame: 0-24 hours]
No study locations are listed for this record.
Start is estimated for Aug 2022; primary completion for Oct 2022, 2 months later.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Enavogliflozin
Daewoong Pharmaceutical Co. LTD. →